<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121301</url>
  </required_header>
  <id_info>
    <org_study_id>13-110-0006</org_study_id>
    <nct_id>NCT02121301</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)</brief_title>
  <official_title>Phase 2, Single-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophth Sol'n in the Environment and During Challenge in the Controlled Adverse Environment (CAE) Model for the Treatment of DES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitotech, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitotech, SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and&#xD;
      effective compared to placebo for the treatment of the signs and symptoms of dry eye&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, double-masked, randomized, placebo-controlled study comprising 4 visits over&#xD;
      the course of approximately 5 weeks. The study included a 1-week placebo (SkQ1 vehicle)&#xD;
      run-in period between Visit 1 and Visit 2, and approximately 28 days of twice daily (BID)&#xD;
      dosing (Visit 2 - Visit 4). Qualified subjects were randomized 1:1:1 to receive either 1.55&#xD;
      µg/mL SkQ1 ophthalmic solution, 0.155 µg/mL SkQ1 ophthalmic solution, or placebo (vehicle of&#xD;
      SkQ1 ophthalmic solution).&#xD;
&#xD;
      The following primary endpoints were tested:&#xD;
&#xD;
        -  Corneal Fluorescein staining in the inferior region Pre-CAE at Visit 4 (Day 29), as&#xD;
           measured by the Ora Calibra Scale in the worst eye at baseline;&#xD;
&#xD;
        -  Worst dry eye symptom (ocular discomfort, dryness, or grittiness - as determined from&#xD;
           subject diary data recorded during the 1-week run-in period between Visit 1 and Visit 2)&#xD;
           evaluated over the seven days preceding Visit 4 (not including day of visit) during the&#xD;
           treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inferior Corneal Fluorescein Staining</measure>
    <time_frame>Day 29</time_frame>
    <description>The dry eye sign primary efficacy variable of corneal fluorescein staining of the inferior region of the eye measured on a 0-4 point scale where 0 = no staining and 4 = most staining between treatment arms at day 29</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worst Symptom Based on Diary Data</measure>
    <time_frame>Day 29</time_frame>
    <description>Worst dry eye symptom (as determined from subject diary data recorded during the 1-week run-in period) evaluated over the seven days preceding Day 29 during the treatment period. The scale was on a 0-5 range where 0= no symptoms and 5= worst symptoms measured for a number of dry eye symptoms.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Keratoconjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Low Dose SkQ1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose SkQ1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose 0.155µg/mL SkQ1 ophthalmic solution</intervention_name>
    <description>eyedrops</description>
    <arm_group_label>Low Dose SkQ1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose 1.55µg/mL SkQ1 ophthalmic solution</intervention_name>
    <description>eyedrops</description>
    <arm_group_label>High Dose SkQ1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Vehicle) opthalmic solution</intervention_name>
    <description>eyedrops</description>
    <arm_group_label>Placebo (vehicle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be male or female of any race, at least 18 years of age&#xD;
&#xD;
          -  Have provided written informed consent&#xD;
&#xD;
          -  Have a reported history of dry eye syndrome&#xD;
&#xD;
          -  Have a history of use or desire to use eye drops for dry eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any clinically significant eye findings that require therapeutic treatment or may&#xD;
             interfere with study parameters&#xD;
&#xD;
          -  Have previously had LASIK surgery within the last 12 months&#xD;
&#xD;
          -  Have used Restasis® within 30 days of Visit 1&#xD;
&#xD;
          -  Be a woman who is pregnant, nursing or planning a pregnancy&#xD;
&#xD;
          -  Be unwilling to submit a urine pregnancy test if of childbearing potential&#xD;
&#xD;
          -  Have a known allergy and/or sensitivity to the test article or its components,&#xD;
             including the preservative benzalkonium chloride&#xD;
&#xD;
          -  Be currently enrolled in an investigational drug or device study or have used an&#xD;
             investigational drug or device within 30 days of Visit 1&#xD;
&#xD;
          -  Have a condition or be in a situation which the investigator feels may put the subject&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawrence General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lawrence General Hospital</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <results_first_submitted>October 7, 2016</results_first_submitted>
  <results_first_submitted_qc>September 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>SkQ1</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <keyword>Dry Eye Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose SkQ1</title>
          <description>Low Dose 0.155 μg/mL SkQ1 ophthalmic solution</description>
        </group>
        <group group_id="P2">
          <title>High Dose SkQ1</title>
          <description>High Dose 1.55 μg/mL SkQ1 ophthalmic solution</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Vehicle)</title>
          <description>Placebo (vehicle) ophthalmic solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose - SkQ1</title>
          <description>Low Dose 0.155 μg/mL SkQ1 ophthalmic solution</description>
        </group>
        <group group_id="B2">
          <title>High Dose - SkQ1</title>
          <description>High Dose 1.55 μg/mL SkQ1 ophthalmic solution</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Vehicle)</title>
          <description>Placebo (vehicle) ophthalmic solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="10.25"/>
                    <measurement group_id="B2" value="59.5" spread="11.69"/>
                    <measurement group_id="B3" value="64.6" spread="9.76"/>
                    <measurement group_id="B4" value="62" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inferior Corneal Fluorescein Staining</title>
        <description>The dry eye sign primary efficacy variable of corneal fluorescein staining of the inferior region of the eye measured on a 0-4 point scale where 0 = no staining and 4 = most staining between treatment arms at day 29</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose SkQ1</title>
            <description>Low Dose 0.155 μg/mL SkQ1 ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>High Dose SkQ1</title>
            <description>High Dose 1.55 μg/mL SkQ1 ophthalmic solution</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Vehicle)</title>
            <description>Placebo (vehicle) ophthalmic solution</description>
          </group>
        </group_list>
        <measure>
          <title>Inferior Corneal Fluorescein Staining</title>
          <description>The dry eye sign primary efficacy variable of corneal fluorescein staining of the inferior region of the eye measured on a 0-4 point scale where 0 = no staining and 4 = most staining between treatment arms at day 29</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.675"/>
                    <measurement group_id="O2" value="2.07" spread="0.704"/>
                    <measurement group_id="O3" value="2.11" spread="0.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Worst Symptom Based on Diary Data</title>
        <description>Worst dry eye symptom (as determined from subject diary data recorded during the 1-week run-in period) evaluated over the seven days preceding Day 29 during the treatment period. The scale was on a 0-5 range where 0= no symptoms and 5= worst symptoms measured for a number of dry eye symptoms.</description>
        <time_frame>Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose SkQ1</title>
            <description>Low Dose 0.155 μg/mL SkQ1 ophthalmic solution</description>
          </group>
          <group group_id="O2">
            <title>High Dose SkQ1</title>
            <description>High Dose 1.55 μg/mL SkQ1 ophthalmic solution</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Vehicle)</title>
            <description>Placebo (vehicle) ophthalmic solution</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Symptom Based on Diary Data</title>
          <description>Worst dry eye symptom (as determined from subject diary data recorded during the 1-week run-in period) evaluated over the seven days preceding Day 29 during the treatment period. The scale was on a 0-5 range where 0= no symptoms and 5= worst symptoms measured for a number of dry eye symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="0.993"/>
                    <measurement group_id="O2" value="2.52" spread="0.899"/>
                    <measurement group_id="O3" value="2.39" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From dilating drop at Day -7 through end of study (Day 29)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose SkQ1</title>
          <description>Low Dose 0.155 µg/mL SkQ1 opthalmic solution</description>
        </group>
        <group group_id="E2">
          <title>High Dose SkQ1</title>
          <description>High Dose 1.55 µg/mL SkQ1 opthalmic solution</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Vehicle)</title>
          <description>Placebo (vehicle) ophthalmic solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Authorship and manuscript composition will reflect cooperation among all parties involved in the study. Authorship will be established before writing the manuscript. The study sponsor will have the final decision regarding the manuscript and publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gosse B. Bruinsma</name_or_title>
      <organization>Ciurem Pharma Inc</organization>
      <phone>613-866-9609</phone>
      <email>gbb@CIUREM.COM</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

